| This week's sponsor is Veeva. | | | [Webinar] Tufts eClinical Landscape Study: Q&A with Industry Experts
January 16, 2018 | 2pm ET / 11am PT
Hear expert analysis of the 2017 eClinical Landscape Survey, one of the largest, most in-depth surveys of clinical data management professionals that shows the impact of database build delays on trial timelines, as well as the projected increase of data source usage. Register Now |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, January 2, 2018 After a slow 2016, with only 22 new molecular entities, new drug approvals picked back up. Here are the ones that made the grade. |
|
|
Top Stories Of The Week Thursday, January 4, 2018 Big Pharma has pushed through a spate of price increases in recent weeks, and while all of them are sub-10%—the cap some companies have adopted—some of them will cost payers and consumers plenty. One of them, in fact, could be worth $1.2 billion all by itself. Tuesday, January 2, 2018 If you thought 2017 was a game-changer for immuno-oncology, just wait. In the first half of 2018 alone, each of the four major players—Merck, Bristol-Myers Squibb, Roche and AstraZeneca—is expecting a phase 3 data readout that Bernstein analyst Tim Anderson says will be “market-defining.” Sunday, December 31, 2017 The Alzheimer’s field is littered with drug-development failures, but that isn’t deterring a group of British scientists from looking for hope in an unlikely source: diabetes treatments. The team, from Lancaster University, is reporting that an experimental three-part drug originally developed for use in Type 2 diabetes seems to reverse memory loss in mice. Wednesday, January 3, 2018 Proclara Biosciences (once NeuroPhage Pharmaceuticals) has poached Merck Research Labs veteran David Michelson, M.D., as its new chief medical officer. Thursday, December 28, 2017 A Fresenius Kabi cancer drug plant in India savaged by the FDA in the past for hiding serious drug testing issues has been branded with a new warning letter. Friday, December 22, 2017 On a quest to make Revlimid a go-to drug for non-Hodgkin lymphoma, Celgene paired its longtime blockbuster with Rituxan and pitted the two against Rituxan and standard chemo. It was a risky proposition—and it failed. Wednesday, January 3, 2018 Biopharma companies, medical research institutions and healthcare facilities have growing interest in getting more genomics data, and that has translated into new investments. A $58 million financing round DNAnexus completed is just one recent example. Tuesday, January 2, 2018 Sanofi recently canned the development of its Clostridium difficile vaccine, dashing its hopes of winning a license for the first shot against the bacterium that's often found in healthcare facilities. But the drugmaker's loss is a win for Pfizer and Valneva, which boast their own late-stage candidates aiming for a share of a market potentially worth $1 billion. Tuesday, January 2, 2018 A tax on medical device sales has come into force after a last-ditch effort to extend the suspension fell short. The failure to stop the progress of the tax means manufacturers will have to report sales to the Internal Revenue Service and pay 2.3% on revenues generated by products covered by the levy. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Veeva Systems Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems. Presented By: Patheon When a biologics company prepares to launch a new product, it must forecast the capacity it will need. Download Patheon's whitepaper to learn how to mitigate risks by developing a manufacturing strategy that will accommodate a forecast range and allow you to adapt as better data becomes available. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. |
